Home » Topics » BioWorld Science, Dermatologic

BioWorld Science, Dermatologic
RSS

miRagen Therapeutics begins first clinical trial for antifibrosis candidate MRG-201

Nov. 16, 2015

Derma Sciences reports results of futility analyses for phase III trials of aclerastide

Nov. 13, 2015

BMS starts phase I study of psoriasis candidate BMS-986165

Nov. 13, 2015

LEO Pharma to acquire global dermatology portfolio from Astellas Pharma

Nov. 12, 2015

Biosimilar etanercept achieves endpoints in phase III psoriasis study

Nov. 10, 2015

InMed provides update on development program for epidermolysis bullosa

Nov. 9, 2015

Calcipotriol formulation has promising effects in patients with nail psoriasis

Nov. 6, 2015

Osiris Therapeutics confirms addition to its wound care portfolio

Nov. 6, 2015

Phase II study of AQX-1125 in atopic dermatitis does not meet primary endpoint

Nov. 5, 2015

OliX Pharmaceuticals discloses its cell-penetrating asymmetric siRNA technology

Nov. 5, 2015

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 21, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...